1. Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐like peptide‐1 receptor agonists
- Author
-
Anders Hasager Boss, Julio Rosenstock, Lizheng Shi, Robert Lubwama, Xuejun Victor Peng, Francisco Javier Ampudia-Blasco, and Vivian Fonseca
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Insulins ,030209 endocrinology & metabolism ,Glycemic Control ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Glucagon-Like Peptide-1 Receptor ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,GLP‐1 analogue ,Internal medicine ,cohort study ,Internal Medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Medicine ,basal insulin ,Retrospective Studies ,Glycated Hemoglobin ,database research ,business.industry ,Medical record ,Hazard ratio ,Retrospective cohort study ,Original Articles ,medicine.disease ,Glucagon-like peptide-1 ,Confidence interval ,glycaemic control ,Diabetes Mellitus, Type 2 ,Pharmaceutical Preparations ,Cohort ,Original Article ,type 2 diabetes ,business ,Cohort study - Abstract
Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on oral antihyperglycaemic drugs with an HbA1c of 9% or higher. Methods This retrospective cohort study assessed the impact of the timing of initiating both basal insulin and GLP‐1 RA therapies on reaching glycaemic targets (HbA1c
- Published
- 2020
- Full Text
- View/download PDF